Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 13;22(1):7.
doi: 10.1186/s13053-024-00277-5.

The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations

Collaborators, Affiliations

The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations

Steven A Narod et al. Hered Cancer Clin Pract. .

Abstract

Background: It has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations.

Methods: We report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations. Women were followed from the date of baseline questionnaire to the diagnosis of skin cancer, to age 80 years, death from any cause, or the date of last follow-up.

Results: During the mean follow-up period of eight years, 3.7% of women with a BRCA1 mutation (133 of 3,623) and 3.8% of women with a BRCA2 mutation (99 of 2,584) reported a diagnosis of skin cancer (including both keratinocyte carcinomas and melanoma). The cumulative risk of all types of skin cancer from age 20 to 80 years was 14.1% for BRCA1 carriers and 10.7% for BRCA2 carriers. The cumulative risk of melanoma was 2.5% for BRCA1 carriers and 2.3% for BRCA2 carriers, compared to 1.5% for women in the general population in the United States. The strongest risk factor for skin cancer was a prior diagnosis of skin cancer.

Conclusion: The risk of non-melanoma skin cancer in women who carry a mutation in BRCA1 or BRCA2 is similar to that of non-carrier women. The risk of melanoma appears to be slightly elevated. We suggest that a referral to a dermatologist or primary care provider for BRCA mutation carriers for annual skin examination and counselling regarding limiting UV exposure, the use of sunscreen and recognizing the early signs of melanoma might be warranted, but further studies are necessary.

Keywords: BRCA1; BRCA2; Basal cell carcinoma; Melanoma; Skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

Cited by

References

    1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol May. 2012;166(5):1069–80. doi: 10.1111/j.1365-2133. - DOI - PubMed
    1. Global Cancer Observatory. Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr, accessed [01/13/2022]. 2020.
    1. Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs Aug. 2013;29(3):160–9. doi: 10.1016/j.soncn.2013.06.002. - DOI - PubMed
    1. Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol Mar. 2016;74(3):395–407. doi: 10.1016/j.jaad.2015.08.038. - DOI - PMC - PubMed
    1. Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol Dec. 2014;20(36):4155–61. doi: 10.1200/JCO.2014.58.2569. - DOI - PubMed